1621090-64-9

Basic information

• Product Name: diethyl 4-(3-fluorobenzyloxy)-1,3-phenylene dicarbamate
• Synonyms: diethyl 4-(3-fluorobenzyloxy)-1,3-phenylene dicarbamate
• CAS NO: 1621090-64-9
• Molecular Weight: 376.385
• Mol File: 1621090-64-9.mol

Chemical Properties

• CAS DataBase Reference: diethyl 4-(3-fluorobenzyloxy)-1,3-phenylene dicarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl 4-(3-fluorobenzyloxy)-1,3-phenylene dicarbamate(1621090-64-9)
• EPA Substance Registry System: diethyl 4-(3-fluorobenzyloxy)-1,3-phenylene dicarbamate(1621090-64-9)

Safety Data

• Hazardous Substances Data: 1621090-64-9(Hazardous Substances Data)

Upstream product

• 1621090-57-0 4-(3-fluorobenzyloxy)benzene-1,3-diamine 
• 541-41-3 chloroformic acid ethyl ester 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 51-28-5 2,4-Dinitrophenol 
• 1621090-50-3 1-(3-fluorobenzyloxy)-2,4-dinitrobenzene 

Downstream Products

• 1621090-70-7 6-(3-fluorobenzyloxy)quinazolin-7-amine 
• 1621090-22-9 1-(6-(3-fluorobenzyloxy)quinazolin-7-yl)-3-p-tolylurea 
• 1621090-23-0 1-(6-(3-fluorobenzyloxy)quinazolin-7-yl)-3-(3-fluorophenyl)urea 

Relevant articles and documents

6-Benzyloxyquinazolin-7-ylurea derivatives with an anticancer activity

The present invention relates to a 6-benzyloxyquinazoline-7-ylurea derivative having anticancer activity and, more specifically, to a 6-benzyloxyquinazoline-7-ylurea derivative represented by chemical formula 1 and a compound selected from pharmaceuticall

Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: Cell line-based assay, kinase panel, molecular docking, and toxicity studies

Herein, we report compound KST9046, a new agent possessing quinazoline-urea scaffold. Preliminary biological evaluation done by the National Cancer Institute (NCI), USA, showed a great inhibitory effect of KST9046 over the 60 cell-line tumor panel. Accord

Novel quinazoline-urea analogues as modulators for Aβ-induced mitochondrial dysfunction: Design, synthesis, and molecular docking study

A novel series of twenty-six quinazoline-urea derivatives was designed and synthesized. Their blocking activities against β-amyloid peptide (Aβ) induced mitochondrial permeability transition pore (mPTP) opening were evaluated by JC-1 assay which measured